Jan Philipp Schuchardt1, Inga Schneider2, Ina Willenberg3, Jun Yang4, Bruce D Hammock4, Andreas Hahn2, Nils Helge Schebb3. 1. Institute of Food Science and Human Nutrition, Leibniz University of Hannover, Germany. Electronic address: Schuchardt@nutrition.uni-hannover.de. 2. Institute of Food Science and Human Nutrition, Leibniz University of Hannover, Germany. 3. Institute for Food Toxicology and Analytical Chemistry, University of Veterinary Medicine Hannover, Germany. 4. Department of Entomology and Comprehensive Cancer Center, University of California, Davis, CA, USA.
Abstract
INTRODUCTION: Several supplementation studies with long-chain omega-3 polyunsaturated fatty acids (LC n-3 PUFA) describe an increase of EPA-derived hydroxy, epoxy and dihydroxy fatty acids in blood, while changes in levels of other LC n-3 and n-6 PUFA-derived oxylipins were minor. In order to investigate the kinetics of changes in oxylipin levels in response to LC n-3 PUFA ingestion, we conducted a single dose treatment study with healthy subjects. SUBJECTS AND METHODS: In the present kinetic study, we compared patterns of hydroxy, epoxy and dihydroxy fatty acids in plasma of 6 healthy men before and after 6, 8, 24, and 48h of fish oil (1008mg EPA and 672mg DHA) ingestion. Levels of EPA- as well as other LC PUFA-derived hydroxy, epoxy and dihydroxy fatty acids were analyzed in plasma by LC-MS. Additionally, levels of these oxylipins were compared with their parent PUFA levels in plasma phospholipids. RESULTS: All EPA-derived oxylipin levels were significantly increased 6h after LC n-3 PUFA ingestion and gradually drop thereafter reaching the baseline levels about 48h after treatment. The relative increase in EPA plasma phospholipid levels highly correlated with the increase of plasma EPA-derived oxylipin levels at different time points. In contrast, plasma levels of arachidonic acid- and DHA-derived oxylipins as well as parent PUFA levels in plasma phospholipids were hardly changed. DISCUSSION AND CONCLUSIONS: Our findings demonstrate that a single dose of LC n-3 PUFAs can rapidly induce a shift in the EPA oxylipin profile of healthy subjects within a few hours. Taking the high biological activity of the EPA-derived epoxy fatty acids into account, even short-term treatment with LC n-3 PUFAs may cause systemic effects, which warrant further investigation.
INTRODUCTION: Several supplementation studies with long-chain omega-3 polyunsaturated fatty acids (LC n-3 PUFA) describe an increase of EPA-derived hydroxy, epoxy and dihydroxy fatty acids in blood, while changes in levels of other LC n-3 and n-6 PUFA-derived oxylipins were minor. In order to investigate the kinetics of changes in oxylipin levels in response to LC n-3 PUFA ingestion, we conducted a single dose treatment study with healthy subjects. SUBJECTS AND METHODS: In the present kinetic study, we compared patterns of hydroxy, epoxy and dihydroxy fatty acids in plasma of 6 healthy men before and after 6, 8, 24, and 48h of fish oil (1008mg EPA and 672mg DHA) ingestion. Levels of EPA- as well as other LC PUFA-derived hydroxy, epoxy and dihydroxy fatty acids were analyzed in plasma by LC-MS. Additionally, levels of these oxylipins were compared with their parent PUFA levels in plasma phospholipids. RESULTS: All EPA-derived oxylipin levels were significantly increased 6h after LC n-3 PUFA ingestion and gradually drop thereafter reaching the baseline levels about 48h after treatment. The relative increase in EPA plasma phospholipid levels highly correlated with the increase of plasma EPA-derived oxylipin levels at different time points. In contrast, plasma levels of arachidonic acid- and DHA-derived oxylipins as well as parent PUFA levels in plasma phospholipids were hardly changed. DISCUSSION AND CONCLUSIONS: Our findings demonstrate that a single dose of LC n-3 PUFAs can rapidly induce a shift in the EPAoxylipin profile of healthy subjects within a few hours. Taking the high biological activity of the EPA-derived epoxy fatty acids into account, even short-term treatment with LC n-3 PUFAs may cause systemic effects, which warrant further investigation.
Authors: Cosima Arnold; Marija Markovic; Katrin Blossey; Gerd Wallukat; Robert Fischer; Ralf Dechend; Anne Konkel; Clemens von Schacky; Friedrich C Luft; Dominik N Muller; Michael Rothe; Wolf-Hagen Schunck Journal: J Biol Chem Date: 2010-08-23 Impact factor: 5.157
Authors: Christophe Morisseau; Bora Inceoglu; Kara Schmelzer; Hsing-Ju Tsai; Steven L Jinks; Christine M Hegedus; Bruce D Hammock Journal: J Lipid Res Date: 2010-07-27 Impact factor: 5.922
Authors: Yuriko Adkins; Benjamin J Belda; Theresa L Pedersen; Dawn M Fedor; Bruce E Mackey; John W Newman; Darshan S Kelley Journal: Lipids Date: 2017-04-13 Impact factor: 1.880
Authors: James F Markworth; Gunveen Kaur; Eliza G Miller; Amy E Larsen; Andrew J Sinclair; Krishna Rao Maddipati; David Cameron-Smith Journal: FASEB J Date: 2016-07-26 Impact factor: 5.191
Authors: Nils Helge Schebb; Annika I Ostermann; Jun Yang; Bruce D Hammock; Andreas Hahn; Jan Philipp Schuchardt Journal: Prostaglandins Other Lipid Mediat Date: 2014-05-29 Impact factor: 3.072
Authors: Stefania Lamon-Fava; Jisun So; David Mischoulon; Thomas R Ziegler; Boadie W Dunlop; Becky Kinkead; Pamela J Schettler; Andrew A Nierenberg; Jennifer C Felger; Krishna Rao Maddipati; Maurizio Fava; Mark Hyman Rapaport Journal: Prostaglandins Leukot Essent Fatty Acids Date: 2020-12-05 Impact factor: 4.006
Authors: Teresa Buckner; Lauren A Vanderlinden; Randi K Johnson; Brian C DeFelice; Patrick M Carry; Jennifer Seifert; Kathleen Waugh; Fran Dong; Oliver Fiehn; Michael Clare-Salzler; Marian Rewers; Jill M Norris Journal: Pediatr Res Date: 2020-07-29 Impact factor: 3.756